ChrysCapital pays ₹1,446 crore for a 70.7% controlling stake in Novartis India, its first majority pharma bet in the country. The PE firm plans to build a branded-generics platform, tapping NIL's legacy brands.
Alpha Score of 50 reflects moderate overall profile with moderate momentum, poor value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Private equity firm ChrysCapital has taken control of Novartis India Ltd (NIL), acquiring a 70.68% stake from Swiss parent Novartis AG for ₹1,446 crore. The deal marks ChrysCapital's first majority-owned investment in the Indian pharmaceutical sector.
NIL was put up for sale after Novartis said in 2024 that its India-listed unit was under strategic review. The transaction, announced in February, values the entire company at roughly ₹2,046 crore. NIL will adopt a new name and corporate identity to formally separate from the Swiss drugmaker.
ChrysCapital plans to use the acquisition as a platform to build a branded-generics business in India. NIL operates across pain management, calcium supplementation, gynecology, neurosciences, and transplant immunology. Its portfolio includes brands such as Voveran, Calcium Sandoz, and Tegrital.
The PE firm has appointed Dr. Vikas Gupta as Chief Executive and Managing Director of NIL. Ramesh Ramadurai, Suchita Sharma, and Shashank Sinha have joined the board as independent directors.
“Combined with NIL's legacy brands and market standing, ChrysCapital believes the foundation for long-term value creation is firmly in place,” said Kshitij Sheth, Managing Director at ChrysCapital Advisors.
Dr. Gupta said the company will build on its existing strengths. “We carry forward decades of scientific rigor and physician trust. From that strong foundation and with ChrysCapital’s backing we have the resources and focus to grow our portfolio with purpose, reach more patients, and build on what this organization has always stood for.”
Kotak acted as exclusive financial advisor to Novartis AG. Freshfields and AZB & Partners provided legal counsel, and Ernst & Young handled financial and tax diligence. For ChrysCapital, Shardul Amarchand Mangaldas & Co acted as legal counsel, while Alvarez & Marsal, Dhruva Advisors, and Price Waterhouse & Co. were financial and tax advisors.
Novartis AG (NVS) carries an AlphaScala Alpha Score of 57 out of 100, a Moderate rating. The Swiss parent retains a minority stake in NIL after the sale.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.